SAT0341 PREDICTORS TO PROGRESSION TO SYSTEMIC SCLEROSIS IN A GROUP OF SECONDARY RAYNAUD PHENOMENON OBSERVED IN A LARGE SINGLE BRAZILIAN COHORT

Background:The 2013 ACR/EULAR classification criteria for systemic sclerosis (SSc) allowed the inclusion of a subset of patients without skin involvement, emphasizing the need of early diagnosis of SSc.Objectives:In this setting, the objective of this study was to classify, according to ACR/EULAR SSc criteria, patients with Raynaud phenomenon (RP) and at least one SSc manifestation, except for skin involvement, and analyze predictors for development of SSc.Methods:This is a cross-sectional single-center analysis of consecutive patients presenting RP and a characteristic SSc manifestation (SSc autoantibody, SSc visceral involvement or SD pattern at nailfold capillaroscopy - NFC), without skin involvement, who attended a scleroderma outpatient clinic between 2010 and 2019. Patients were classified as SSc (according to ACR/EULAR SSc criteria) or undifferetiated connective tissue disease (UCTD) in their last medical visit and compared. Additionally, a longitudinal retrospective analysis of both groups was performed to find predictors for development of SSc. Data were obtained from an electronic register database. Statistical significance was set up as pResults:Among 217 patients, 153 (70.5%) were classified as SSc, at the last medical visit, including 65 (30%) after the first investigation. During a comparable median follow-up [4.9±3.8 vs. 4.6±3.0 years;p=0.90], patients with SSc presented more frequently puffy fingers (PF:73% vs. 6.3%;pvs. 57.8%;pvs. 3.1%;pvs. 10.9%;p=0.048). Furthermore, SSc patients were more frequently treated with immunosuppressive therapy (80.1%vs. 37.5%;pvs. 1.6%;pConclusion:Among patients with RP and SSc features, but without skin involvement, those with SSc had a more severe disease with worse prognosis than UCTD with RP. Puffy fingers and a higher baseline SSc score, especially in combinations including PF or lung disease were predictors of SSc, reinforcing the strength of the ACR/EULAR classification criteria and the presence of specific non-RP symptoms.Disclosure of Interests:Valdirene Siqueira: None declared, Mariely Helbingen: None declared, Ana Paula Luppino-Assad: None declared, Henrique Carriço da Silva: None declared, Danieli Andrade: None declared, Ana Cristina Medeiros-Ribeiro: None declared, Percival D. Sampaio-Barros Consultant of: Abbvie, Boehringer Ingelheim, Lilly, Novartis, Speakers bureau: Abbvie, Janssen, Lilly, Novartis